On Jan. 6, the Food and Drug Administration approved lecanemab, now known as Leqembi, using the accelerated approval pathway. Based on results from very strong clinical trials, leading Alzheimer’s researchers agree this treatment changes the course of the disease in a meaningful way for people with early Alzheimer’s. But because of the decision the Centers for Medicaid & Medicare Services has put into place, Medicare will not cover this treatment.
This is the first time in the history of the Medicare program that it will not cover an FDA-approved treatment upon its approval. CMS’s policy is unjustified, harmful and unfair.
Growing up, I watched my grandmother’s struggle with dementia, and in my role as Delaware’s director of state government affairs for the Alzheimer’s Association, I witness every day the devastating impact of this fatal disease on our community – our loved ones, friends and neighbors. It is time for action! The Alzheimer’s Association has filed a formal request calling on CMS to provide full, unrestricted coverage for Alzheimer’s treatments that have been approved by the FDA. We ask Rep. Lisa Blunt Rochester to join us in urging CMS to provide full coverage for FDA-approved Alzheimer’s drugs, just as it does for FDA-approved drugs for every other disease. I also encourage all Delawareans to learn more about how to join the fight to end Alzheimer’s by going to alzimpact.org.
-
A letter to the editor expresses a reader's opinion and, as such, is not reflective of the editorial opinions of this newspaper.
To submit a letter to the editor for publishing, send an email to viewpoints@capegazette.com. All letters are considered at the discretion of the newsroom and published as space allows. Due to the large volume of submissions, we cannot acknowledge receipt of each submission. Letters must include a phone number and address for verification. Keep letters to 400 words or fewer. We reserve the right to edit for content or length. Letters should be responsive to issues addressed in the Cape Gazette rather than content from other publications or media. Letters should focus on local issues, not national topics or personalities. Only one letter per author will be published every 30 days regarding a particular topic. Authors may submit a second letter within that time period if it pertains to a different issue. Letters may not be critical of personalities or specific businesses. Criticism of public figures is permissible. Endorsement letters for political candidates are no longer accepted. Letters must be the author’s original work, and may not be generated by artificial intelligence tools. Templates, form letters and letters containing language similar to other submissions will not be published.
